

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

SUPPLEMENTAL ANNOUNCEMENT RELATING TO THE RENEWED LEASE AGREEMENTS

Reference is made to the announcement of the Company dated 22 December 2021 (the “**Announcement**”) in relation to the entering into of the Renewed Lease Agreements among certain members of the Group, namely, CSPC NPB, CSPC Ouyi, CSPC Zhongnuo and CSPC Zhongqi (all as tenants) and CHL (as landlord) for a term of three years commencing on 1 January 2022. Capitalised terms used in this announcement shall have the same meaning as defined in the Announcement.

The value of the right-of-use assets under the Renewed Lease Agreements will be recognised by the Group in its consolidated statement of financial position in accordance with the HKFRS 16 applicable to the Group. The value of the right-of-use assets under each of the Renewed Lease Agreements is estimated to be approximately RMB23,265,000 (in respect of Premises 1), RMB57,092,000 (in respect of Premises 2), RMB28,649,000 (in respect of Premises 3) and RMB34,054,000 (in respect of Premises 4), being the estimated present value of the total rental payments payable throughout the term under each of the Renewed Lease Agreements in accordance with HKFRS 16. As one or more of the applicable percentage ratios set out in Rule 14.07 of the Listing Rules in respect of the Renewed Lease Agreements, on the basis of the aggregate of the estimated value of the right-of-use assets mentioned above (i.e. approximately RMB143,060,000), exceed(s) 0.1% but all of them are less than 5%, the Renewed Lease Agreements are subject to the reporting and announcement requirements but are exempt from the circular (including independent financial advice) and independent shareholders’ approval requirements under Chapter 14A of the Listing Rules.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 29 December 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Professor WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.